Host-Targeted Compounds Inhibiting SARS-CoV-2 Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for COVID-19 lack effective solutions to inhibit SARS-CoV-2 entry into cells and manage hyperinflammation, highlighting a need for host-targeted therapies that can induce antiviral and anti-cytokine responses to constrain viral spread.
Innovation Solution
The development of compounds and compositions that identify and utilize host-targeted antiviral and anti-inflammatory agents, such as imipramine, salmeterol, and hexylresorcinol, to stimulate antiviral and anti-cytokine signatures, inhibit viral entry, and reduce hyperinflammation by constructing protein-protein interaction networks and conducting in vitro assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If host-targeted therapies are developed to induce antiviral and anti-cytokine responses, then viral spread can be constrained, but the complexity of identifying and developing effective compounds increases
Solution Approach 1:
The patent performs preliminary computational analysis by obtaining transcriptomic data from infected cells, identifying differentially expressed genes, and characterizing host-targeted antiviral and anti-cytokine signatures before conducting experimental assays. This preliminary bioinformatic screening prioritizes compounds for in vitro testing, reducing the complexity of the overall development process.
Solution Approach 2:
The patent uses an intermediary computational framework that integrates transcriptomic data, protein-protein interaction networks, and compound-target interactions. This intermediary system mediates between the complex biological system and the drug discovery process, enabling systematic evaluation of host-targeted therapies without requiring direct manipulation of every biological variable.
2Reliability
If compounds are screened to inhibit viral entry and reduce hyperinflammation, then therapeutic effectiveness improves, but the time required for compound identification and validation increases
Solution Approach 1:
The patent performs preliminary computational screening using transcriptomic data and protein-protein interaction networks to prioritize compounds before experimental validation. This preliminary action filters and ranks potential therapeutics based on their predicted ability to inhibit viral entry or reduce hyperinflammation, significantly reducing the time required for comprehensive compound screening.
Solution Approach 2:
The patent employs feedback loops where in vitro assay results feed back into the computational modeling to refine compound prioritization. This iterative feedback process allows continuous improvement of the screening criteria, accelerating the identification of effective compounds while maintaining high therapeutic reliability.
Data Source
AI summary
Disclosed herein are methods of identifying a compound for treating or preventing an infection with an infectious microbe, such as a coronavirus, in a subject in need thereof. Also disclosed herein are compounds and compositions identified by said methods, and methods of use thereof.